VLST Corp.
This article was originally published in Start Up
Executive Summary
VLST is developing a platform around the identification and understanding of the function of virulence factors, a set of proteins in viruses that down regulate the host's immune response, thereby conferring a survival advantage. Understanding this evolutionary process can lead to the identification of a group of clinically relevant cellular targets, as the predicate for the development of therapeutics.
You may also be interested in...
A Novel Niche Approach to Antibacterial Drug Development
Researchers are finding new ways to disable bacteria, either by increasing their sensitivity to existing drugs or decreasing their virulence. Targeting bacterial functions that have a significant effect on growth in an infected host but are not thought of as "antimicrobial" may represent an important new drug development strategy. A group recently reported encouraging, if very early, results about the ability of an inhibitor of virulence factor biosynthesis to control tuberculosis infection.
In Inflammation, the Indication's the Thing
With a host of drugs on the market for large inflammatory disease indications like rheumatoid arthritis, start-ups are finding niches elsewhere.
Start-Up Previews (5/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: In Inflammation, the Indication's the Thing, features profiles of Anthera Pharmaceuticals, Logical Therapeutics, Opsona Therapeutics and VLST Corp.. Plus these Start-Ups Across Health Care: Biodesy, Magenta Medical and NuLens.